Literature DB >> 26513703

DANGER IN THE INTENSIVE CARE UNIT: DAMPS IN CRITICALLY ILL PATIENTS.

Kim Timmermans1, Matthijs Kox, Gert Jan Scheffer, Peter Pickkers.   

Abstract

Danger-associated molecular patterns (DAMPs) that are released by injured, threatened, or dead cells, or that originate from the extracellular matrix, influence the immune system. This is of great relevance in critically ill patients, in whom trauma or surgery-related cell damage, hypoxia, ischemia, and infections can result in extensive release of DAMPs. As many patients at the intensive care unit suffer from immune system-related complications, DAMPs could serve as markers for the prognosis of these patients and represent possible therapeutic targets. In the present review, we provide an overview of several well known DAMPs (high-mobility group box 1, heat-shock proteins, s100 proteins, nucleic acids, and hyaluronan) and their effects on the immune system. Furthermore, we discuss the role of DAMPs as markers or therapeutic targets in several conditions frequently encountered in critically ill patients, such as sepsis, trauma, ventilator-induced lung injury, and cardiac arrest.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26513703     DOI: 10.1097/SHK.0000000000000506

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  22 in total

1.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome.

Authors:  Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

Review 2.  Danger Signals in the ICU.

Authors:  Edward J Schenck; Kevin C Ma; Santosh B Murthy; Augustine M K Choi
Journal:  Crit Care Med       Date:  2018-05       Impact factor: 7.598

Review 3.  The sepsis induced defective aggravation of immune cells: a translational science underling chemico-biological interactions from altered bioenergetics and/or cellular metabolism to organ dysfunction.

Authors:  Waleed Hassan Almalki
Journal:  Mol Cell Biochem       Date:  2021-02-14       Impact factor: 3.396

Review 4.  Is Coagulopathy an Appropriate Therapeutic Target During Critical Illness Such as Trauma or Sepsis?

Authors:  Hunter B Moore; Robert D Winfield; Mayuki Aibiki; Matthew D Neal
Journal:  Shock       Date:  2017-08       Impact factor: 3.454

5.  Zymosan-Induced Peritonitis: Effects on Cardiac Function, Temperature Regulation, Translocation of Bacteria, and Role of Dectin-1.

Authors:  Lizzie L Monroe; Michael G Armstrong; Xia Zhang; Jennifer V Hall; Tammy R Ozment; Chuanfu Li; David L Williams; Donald B Hoover
Journal:  Shock       Date:  2016-12       Impact factor: 3.454

Review 6.  Multi-Omics Techniques Make it Possible to Analyze Sepsis-Associated Acute Kidney Injury Comprehensively.

Authors:  Jiao Qiao; Liyan Cui
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

Review 7.  Persistent Inflammation, Immunosuppression and Catabolism Syndrome.

Authors:  Juan C Mira; Scott C Brakenridge; Lyle L Moldawer; Frederick A Moore
Journal:  Crit Care Clin       Date:  2017-04       Impact factor: 3.598

8.  High mobility group box 1 as a biomarker in critically ill patients.

Authors:  Eray Yagmur; Lukas Buendgens; Ulf Herbers; Anne Beeretz; Ralf Weiskirchen; Ger H Koek; Christian Trautwein; Frank Tacke; Alexander Koch
Journal:  J Clin Lab Anal       Date:  2018-06-03       Impact factor: 2.352

9.  ICU-Acquired Weakness, Chronic Critical Illness, and the Persistent Inflammation-Immunosuppression and Catabolism Syndrome.

Authors:  Tyler John Loftus; Frederick Allen Moore; Lyle L Moldawer
Journal:  Crit Care Med       Date:  2017-11       Impact factor: 7.598

10.  Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis.

Authors:  Jaewoo Lee; Jennifer G Jackman; Jean Kwun; Miriam Manook; Angelo Moreno; Eric A Elster; Allan D Kirk; Kam W Leong; Bruce A Sullenger
Journal:  Biomaterials       Date:  2016-12-23       Impact factor: 15.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.